Presentation on theme: "Introducing Rheumadrin® Rheumadrin® is an all natural proprietary ingredient, that has been clinically proven to reduce pain and rapidly promote joint."— Presentation transcript:
Introducing Rheumadrin® Rheumadrin® is an all natural proprietary ingredient, that has been clinically proven to reduce pain and rapidly promote joint health, improving flexibility and mobility. Clinically studied at various times in Vivo, it has been published TWICE in the prestigious Journal of Rheumatology. Available for oral and topical applications, Celadrin's beneficial effects have been proven superior in results to Glucosamine, Chondroitin, MSM, SAMe and other arthritic medications.
What Is Rheumadrin®? Rheumadrin® is comprised of novel, targeted & proprietary cetylated fatty acid esters & other active synergists. Rheumadrin 's proprietary compound is scientifically designed to be absorbed rapidly and provide immediate and continuous/cumulative pain relief. Rheumadrin ®, available for either oral or topical applications, enhances cell membranes throughout the body and restores fluids that cushion bones and joints to promote flexibility and mobility without pain. Rheumadrin ® has been shown to be very safe & efficacious as evidenced by gold standard, double-blind, placebo-controlled clinical & scientific studies. Rheumadrin ® is FDA compliant and non prescriptive.
Benefits of Rheumadrin® Clinically shown for being fast acting (within 30 minutes) with rapid and deep absorption/penetration to the affected area Clinically proven effective in both oral and topical applications 100% of the patients in the study on the proprietary cream showed significant benefit compared to the patients on the placebo Celadrin® will provide speedy relief to aching, painful joints, muscles and tissues No reported negative side effects – over 100 million Rheumadrin ® pills distributed to date For temporary relief of minor aches and pains associated with simple backache, arthritis, strains, bruises and sprains Tremendous market potential, "joint functions and mobility challenges" are a growing segment of muscular-skeletal health challenges that are estimated to cost $250 billion dollars annually, in the U.S. alone
Mechanisms of Action: The fatty acid complex found in Rheumadrin ® is distributed within the various tissues as determined via our radiolabel research. It seems likely that the majority of the product is processed within the liver. The resulting chylomicrons are then distributed within the circulation and made available to the entire cellular matrix. In addition, it is very likely that with both oral and topical use, there is distribution within tissue spaces prior to the first pass through the liver. There is clinical data that Rheumadrin ® can induce, beneficial alterations in the cellular membrane.
Market Potential for Rheumadrin®: Over 70 million individuals in U.S. have arthritis (Center for Disease Control). The Arthritis Foundation reports that arthritis is the leading disability of Americans, resulting in over 39 million medical visits/year and $65 billion dollars annually in medical expenses and lost wages. Joint functions and mobility challenges are a growing segment of musculo-skeletal health challenges that are estimated to cost $250 billion dollars in the U.S. alone. Rheumadrin ® provides restoration of arthritic conditions for a much larger potential market than Glucosamine. Rheumadrin ® could be added to current leading compounds (Chondroitin, Glucosamine, SAMe, etc..) or product formulas, to increase efficacy and product sales. For Marketers involved in veterinary sales, Rheumadrin ® has been studied to be effective in canines. The canine population in the U.S. is 53 million, 20% of which suffer from osteoarthritis (OA). Rheumadrin ® can be proven to be more effective than Glucosamine and Chondroitin products, currently sold in this market segment.
Estimated size of pain pie population is 120 million Market Potential for Rheumadrin®: Rheumadrin® provides restoration of arthritic conditions from osteo, rheumatoid, tendonitis, bursitis, fibromyalgia, plus over 100 other types of arthritis, sports injuries to joints, muscles, tendons and deep tissue 85% of total population of 120 million Glucosamine provides restoration of Osteoarthritis 15% of total population of 120 million PAIN PIE BENEFIT Conditions Rheumadrin® & Glucosamine Alleviate:
RHEUMADRIN® COMPARISON TO COMPETITIVE COMPOUNDS Market Potential for Rheumadrin®:
Scientific Studies: Scientific Evaluations of Rheumadrin® have demonstrated: Esterified Fatty Acid Complex (EFAC) found in Rheumadrin ® can be effectively absorbed in either oral or topical form and delivered to the required area of pain in the body. In clinical studies using oral and topical applications, patients with chronic knee problems and Osteoarthritis (OA) produced significant improvement in knee movement, the ability to climb and descend stairs, rise from chairs, improvement in walking, balance, strength and endurance. More significant was that in one of the studies, patients were already consuming arthritis medications (Aspirin, Ibuprofen or Celecoxib) and still demonstrated significant improvement with Rheumadrin ®. Product safety confirmation through Acute Toxicity testing and Ames test screening have been conducted.
Scientific Studies: No adverse effects or reactions such as upset stomach (oral) or skin irritations (topical). Anti-aging potential benefits were observed in laboratory mice by measuring skin thickness. A 30 day canine study of Rheumadrin ®, using 24 arthritic dogs resulted in a 75% improvement in the quality of life of the pets, as noted by their owners. Dogs appeared "happier", "more energetic", had "better temperament" and an overall improved "Quality Of Life (QOL)". A small (14 subject) placebo controlled blind study, using Rheumadrin ® Cream showed measurable improvement in subject's with severe psoriatic condition. Scientific Evaluations of Rheumadrin® have demonstrated (continued) :
Scientific Studies: Kraemer WJ, Ratamess NA, Anderson JA, Tiberio DP, Joyce ME, Messinger BN, French DN, Sharman MJ, Rubin MR, Gomez AL, Volek JS, Hesslink R Jr. (2003) The effects of cetylated fatty acid cream on pain, range of motion and quality of life of patients with osteoarthritis. American College of Sports Medicine, San Francisco, CA. A 30 day study conducted on patients with (OA) in both knees. Conclusion, use of EFAC cream is an effective treatment for improving knee (ROM) movement, ability to ascend/descend stairs, rise from a chair, walk and improve balance, strength and endurance. Ratamess NA, Kraemer WJ, Anderson JA, Tiberio DP, Joyce ME, Messinger BN, French DN, Sharman MJ, Rubin MR, Gomez AL, Volek JS, Hesslink R Jr. (2003) The effects of a cetylated fatty acid cream on functional mobility and performance in patients with osteoarthritis. American College of Sports Medicine, San Francisco, CA. This Rheumadrin® cream study concluded that the use of EFAC topical cream produced significant improvement in stair climbing ability, standing balance, local muscular endurance and ability to rise from a chair and walk, in patients with OA.
Scientific Studies: Islam A, Gallaher C.M., & Gallaher D.D. (2003) Absorption & metabolism of a cetylated fatty acid. Experimental Biology, San Diego, CA. This study successfully measured the absorption of EFAC in 10 rats using topical and oral applications. It was proven that EFAC could be absorbed by either method (95.1% absorption of radio labeled EFAC's). Gallaher D.D., Gallaher C.M., Hesslink R. Jr. (2002) Digestion and metabolism of cetylated fatty acids in rats. Experimental Biology, New Orleans, LA Successfully demonstrated oral absorption of EFAC’s. Hesslink R.L., and Sprouse S. (2002) The effects of a cetylated fatty acid complex on canine osteoarthritis. 2nd International Symposium on Rehabilitation and Physical Therapy in Veterinary Medicine, Knoxville, TN. 30 day trial of 24 arthritic canines. Owners noted 75% improvement in quality of life, energy & movement. Barathur R. R., Bookout J.B., Sreevatsan S, Freedland E.S. and Hesslink Jr., R.L. (2001). A fatty acid ester (CMC) improves quality of life outcomes in osteoarthritis (OA) patients. Experimental Biology, Orlando, FL.
Publications: Kraemer W.J., Ratamess N.A., Anderson J.A., Maresh C.M., Tiberio D.P., Joyce M.E., Messinger B.NB., French D.N., Sharman M.J., Rubin M.R., Gomez A.L., Volek J.S. & Hesslink, Jr., R.L. (2003) The effects of a cetylated fatty acid topical cream on functional mobility & quality of life of patients with osteoarthritis. In review, J. Rheumatology Topical Cream Study – no menthol. Hesslink Jr. R.L., Armstrong III D.A., Nagendran M.V., Sreevatsan S, & Barathur R. (2002) Cetylated fatty acids improve knee function in patients with osteoarthritis. J Rheumatology, 29:1708-1712 64 patients with chronic knee problems at 30 & 68 days (also placebo group - 33 Celadrin - 31 vegetable oil). Results: significant increase in knee flexatition with Rheumadrin®. More significant was that patients were consuming arthritis medication such as Aspirin, Ibuprofen and Celecoxib. Islam A, Gallaher C.M., & Gallaher D.D. (2003) Absorption & metabolism of a cetylated fatty acid. FASEB J. 17(4): A341 Gallaher D.D., Gallaher C.M., Hesslink R. Jr. (2002) Digestion & metabolism of cetylated fatty acids in rats. FASEB J. 16 (4): A365 Barathur R.R., Bookout J.B., Sreevatsan S, Freedland E.S. & Hesslink Jr., R.L. (2001). A fatty acid ester (CMC) improves quality of life outcomes in osteoarthritis (OA) patients. FASEB J. 15(4): A265
Technical Reports: Bacterial reverse mutation Ames test screening. (2002) MDS Pharma, Les Oncins, France. Evaluation of topical cetylated fatty acid application to psoriasis patients. (2002) Dermatologist Medical Group of North County, Inc. A small placebo controlled blind study using Rheumadrin® cream experienced measurable improvement in their psoriatic condition. The acute toxicology of oral cetylated fatty acid gavage CD-1 mouse model. (2001) Perry Scientific, Inc., Study No. 00-1075. Evaluation of a topical cream containing cetylated fatty acids using hairless mouse model. (2000) Perry Scientific, Inc., Study No. 00-1076. Objectives were to assess potential skin irritations, cellular pathology and skin aging. Mice were measured at 10, 58 and 144 days. Mice behavior was normal, no signs of skin irritations or abnormalities in cell lines. Anti-aging benefits were observed measuring the comparative skin thickness of the mice.